Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience
- 353 Downloads
In patients with advanced differentiated thyroid carcinoma (DTC), therapy with the highest safe 131I activity is desirable to maximize the tumour radiation dose yet avoid severe myelotoxicity. Recently, the European Association of Nuclear Medicine (EANM) published a standard operational procedure (SOP) for pre-therapeutic dosimetry in DTC patients incorporating a safety threshold of a 2 Gy absorbed dose to the blood as a surrogate for the red marrow. We sought to evaluate the safety and effectiveness in everyday tertiary referral centre practice of treating advanced DTC with high 131I activities chosen primarily based on the results of dosimetry following this SOP.
We retrospectively assessed toxicity as well as biochemical and scintigraphic response in our first ten patients receiving such therapy for advanced DTC.
The 10 patients received a total of 13 dosimetrically guided treatments with a median administered activity of 14.0 GBq (range: 7.0–21.4 GBq) 131I. After 6 of 13 treatments in 6 of 10 patients, short-term side effects of 131I therapy, namely nausea, vomiting or sialadenitis, were observed. Leukocyte and platelet counts dropped significantly in the weeks after 131I treatment, but returned to pre-treatment levels by 3 months post-therapy. Serum thyroglobulin levels decreased after 12 of 13 treatments (median reduction: 58%) in 9 of 10 patients.
In our initial patient cohort, high-activity 131I therapy for advanced DTC based on pre-therapeutic blood dosimetry following the EANM SOP was safe and well tolerated. Such treatment almost always produced a partial biochemical tumour response.
KeywordsDifferentiated thyroid cancer Dosimetry 131I therapy EANM standard operating procedure Metastases
We would like to thank Robert J. Marlowe for his invaluable extensive editorial assistance.
- 5.Benua RS, Leeper RD. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. In: Medeiros-Neto G, Gaitan G, editors. Frontiers in thyroidology. New York: Plenum Medical Book Co; 1986. p. 1317–21.Google Scholar
- 6.Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405–12.CrossRefPubMedGoogle Scholar
- 7.Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648–54.PubMedGoogle Scholar
- 9.Common terminology criteria for adverse events v3.0 (CTCAE). Rockville, MD: National Cancer Institute, 2006.Google Scholar